Evidence map›Paper›PMID 41187013›Full record

Trial reportObesity (Silver Spring, Md.)2026

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.

Xuan Li, Dachuang Cao, Helene Sapin, Fangyu Wang, Theresa Hunter Gibble, Nedina Kalezic Raibulet, Max Denning, Lee M Kaplan

3 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04184622. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04184622 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Ran2019Enrolled2,539Registered outcomes26Posted comparisons49ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
NCT04657016 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)

Ran2021Enrolled579Registered outcomes22Posted comparisons22ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
NCT04660643 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Ran2021Enrolled783Registered outcomes26Posted comparisons41ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuan LiEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-6169-2640
Dachuang CaoEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-2291-9037
Helene SapinEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-2602-8450
Fangyu WangEli Lilly and Company, Indianapolis, Indiana, USA.
Theresa Hunter GibbleEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-8412-9175
Nedina Kalezic RaibuletEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-5814-0036
Max DenningEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-6215-6885
Lee M KaplanGeisel School of Medicine at Dartmouth and Dartmouth Health, Hanover, New Hampshire, USA.ORCID https://orcid.org/0000-0002-6301-2696

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

objectiveThis post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity-related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide-led improvements in PF was evaluated.

methodsOutcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF). Least-squares mean changes from baseline in efficacy measures and PF were estimated using ANCOVA. Pearson's correlation between weight reduction and improvement in PF was calculated.

resultsIn SURMOUNT-1, participants with lower baseline PF had more ORCs. Tirzepatide-treated participants showed similar reductions in weight (kg; -20.1% to -22.8%), waist circumference (-17.2 to -20.2 cm), and BMI (-7.2 to -9.0 kg/m

conclusionsLower baseline PF was associated with a higher prevalence of ORCs. Patients taking tirzepatide experienced substantial weight loss, regardless of their baseline PF. Tirzepatide may improve PF through both weight loss-dependent and -independent mechanisms, especially in those with lower baseline PF.

trial registrationClinicalTrials.gov identifiers: SURMOUNT-1, NCT04184622; SURMOUNT-3, NCT04657016; SURMOUNT-4, NCT04660643.

Indexed as

Anti-Obesity AgentsObesityAdultBody Mass IndexFemaleHumansMaleMiddle AgedTirzepatideTreatment OutcomeWaist CircumferenceWeight LossAnti-Obesity AgentsTirzepatidehealth‐related quality of lifeobesitypatient‐reported outcomesphysical functiontirzepatide

Identifiers

PMID41187013
PMCPMC12724063

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.